Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Competition for XF-73 moves aside, issue approved
Our previous note discussed Destiny’s acquisition of the Phase 3-ready NTCD M3 product for the...
Read moreA group transformed
While completing the Phase 2b study of their first product, Destiny have announced the planned...
Read morePlenty of progress in H1
Having navigated the challenge of running a clinical trial during a global pandemic, Destiny has...
Read moreYet another string to Destiny's bow
Destiny Pharma have always had a microbiome tilt with their most advanced product, topical XF-73,...
Read more
New Model Anti-infectives
Destiny's lead product XF-73 is in the US and European Phase 2b study for a new preventative...
Read moreDifferentiated drugs
FY 2019 results featured its ongoing Phase IIb study of its lead drug XF-73 for the prevention of...
Read moreAnti-microbial agents with unique properties
Following the set of largely established US and EU guidelines which recommend the decolonisation of...
Read moreBucking the Big Pharma trend
Lead asset XF-73 has potential to be first to a $1.2bn core market. We think that its low...
Read moreExtending the clinical pipeline
Their pipeline of novel antimicrobials include eight so far tested of those classed as urgent...
Read moreClinical progress with XF drug platform
Recently, positive results from a blinded, placebo-controlled Phase I dermal irritancy study of...
Read moreWell-funded and on track for Phase IIb
Destiny is on target for delivering the clinical plan for its novel antimicrobial candidate XF-73...
Read moreRegister to be first
Get research on the companies that interest you straight to your inbox
